383 results
Responsible body
PRAC Remove PRAC filter
-
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9 - 12 January 2023 (new)
PRAC, Last updated: 13/01/2023 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 November - 1 December 2022
PRAC, Last updated: 02/12/2022 -
List item
News: EMA recommends withdrawal of pholcodine medicines from EU market
PRAC, Last updated: 02/12/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24 - 27 October 2022
PRAC, Last updated: 28/10/2022 -
List item
News: EMA confirms recommendation to withdraw marketing authorisations for amfepramone medicines
PRAC, Last updated: 28/10/2022 -
List item
News: EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders
PRAC, Last updated: 03/11/2022 -
List item
News: New recommendations for terlipressin-containing medicines in the treatment of hepatorenal syndrome
PRAC, Last updated: 30/09/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26-29 September 2022
PRAC, Last updated: 30/09/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 August – 1 September 2022
PRAC, Last updated: 02/09/2022 -
List item
News: Review of pholcodine medicines started
PRAC, Last updated: 02/09/2022 -
List item
News: PRAC starts review of topiramate use in pregnancy and women of childbearing potential
PRAC, Last updated: 02/09/2022 -
List item
News: Medicines containing nomegestrol or chlormadinone: PRAC recommends new measures to minimise risk of meningioma
PRAC, Last updated: 08/07/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 July 2022
PRAC, Last updated: 08/07/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 June 2022
PRAC, Last updated: 10/06/2022 -
List item
News: EMA recommends withdrawal of marketing authorisation for amfepramone medicines
PRAC, Last updated: 10/06/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 May 2022
PRAC, Last updated: 06/05/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 April 2022
PRAC, Last updated: 08/04/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 March 2022
PRAC, Last updated: 11/03/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7 - 10 February 2022
PRAC, Last updated: 11/02/2022 -
List item
News: EMA starts safety review of Janus kinase inhibitors for inflammatory disorders
PRAC, Last updated: 11/02/2022 -
List item
News: PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market
PRAC, Last updated: 11/02/2022 -
List item
News: COVID-19: EMA recommends conditional marketing authorisation for Paxlovid
CHMP, PRAC, Last updated: 28/01/2022 -
List item
News: COVID-19: latest safety data provide reassurance about use of mRNA vaccines during pregnancy
CHMP, PRAC, Last updated: 18/01/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 - 13 January 2022
PRAC, Last updated: 14/01/2022 -
List item
News: EMA receives application for conditional marketing authorisation for Paxlovid (PF-07321332 and ritonavir) for treating patients with COVID-19
CHMP, PRAC, Last updated: 10/01/2022